The oncolytic properties of talimogene laherparepvec result in the release of tumor-derived antigens in an immune stimulatory microenvironment, local production of GM-CSF, and cross-priming of CD8+ T-cell responses by dendritic cells, which facilitate an immune response against the tumor [12]. The gene discussed is CSF2; the disease is neoplasm.